

Remit:

The Area Drug and Therapeutics Committee (ADTC) provides leadership for the medicines agenda across the full NHS Greater Glasgow & Clyde (GG&C) system on behalf of the NHS Board. The overall aim is to provide a strategic lead to promote good quality and cost-effective prescribing, within the principles of Realistic Medicine, throughout NHS GG&C (Acute Services, Partnerships and Primary Care). The work of the ADTC covers a range of strategic, operational, professional and financial aspects of medicine management. In doing so, the ADTC and subcommittees support collaboratively the work of national bodies e.g. Scottish Medicines Consortium (SMC), National Institute for Health and Clinical Excellence (NICE), Healthcare Improvement Scotland (HIS), Scottish Intercollegiate Guidelines Network (SIGN) etc.

Functions:

The core functions of the Area Drugs and Therapeutics Committee will be to:

- promote the safe, effective and efficient use of medicines within the principles of realistic medicine to maximise health gains for patients;
- develop co-ordinated policies and treatment guidelines for the cost effective use of medicines;
- address strategic issues which relate to prescribing practice and medicines management;
- advise on the introduction of new medicines and monitor their utilisation through effective governance structures;
- develop and maintain the NHS Greater Glasgow & Clyde Formularies and Therapeutics Handbook;
- liaise with Managed Clinical Networks and other specialist clinical interest groups to influence and seek advice on aspects of prescribing practice
- Manage prescribing across the primary care-secondary care interface
- monitor critical incidents relating to medicines and disseminate knowledge gained from lessons learned;
- review and monitor safe medication practices and promote implementation to improve patient safety;
- encourage participation in the 'Yellow Card' scheme for reporting of adverse drug reactions;
- promote, support and monitor the development of non-medical prescribers, including coordination of a systematic process to improve access to medicines through Patient Group Directions;
- adopt, implement and monitor strategies that support the optimal stewardship of antimicrobial agents;
- encourage research and audit on the cost-effective use of medicines;
- develop a system for managing risks identified with the work of the Committee;
- co-ordinate a comprehensive approach to addressing national policy documents relating to medicines;
- provide timely communication of ADTC policy and decisions to health professionals, patients and the public

Date of last revision: 14/08/2024

Date Approved: 30/10/2023

Date for Review: 30/10/2026



To fulfil this remit the Committee is supported by a number of Sub-Committees:

- (a) Medicines Utilisation
- (b) Safer Use of Medicines
- (c) Non-Medicines Utilisation
- (d) Antimicrobial Utilisation
- (e) Communications
- (f) Prescribing Interface
- (g) Patient Group Directions

These Sub-Committees have supplementary Terms of Reference and some also have additional lines of accountability beyond the ADTC.

Membership:

The ADTC will have a Chair, two Vice Chairs, Professional Secretary and a wide ranging membership, with representation from:-

Acute Care Sectors:

- North and West
- South
- Clyde
- Women & Children's
- Regional Services Primary Care:
- General Practitioners (including representation of Local Medical Committee)
 Chairs of Sub-Committees
 Clinical Pharmacologist
 Antimicrobial Management Team

Nursing Pharmacy Services:

- Acute Services
- Medicines Information
- Prescribing Advisors and Prescribing Support
- Non-medical Prescribing Clinical Governance Clinical Specialists (as appropriate) Dentistry

One member may represent more than one part of the organisation. Broad geographical representation is desirable. Other members may be co-opted to reflect organisational structures within NHS GG&C. The above list is not intended to exclude from membership any individual with particular interest or expertise. Whenever a membership vacancy arises, the Chair or Vice Chair(s) should identify a replacement and should forward this nomination for approval by the ADTC Executive.

A normal term of office for Committee Members will be three years, but with the option to continue for two further terms of office thereafter, or longer at the discretion of the ADTC Executive. It is anticipated that there will be regular rotation of membership to provide a balance of experience on the Committee.

File name: 2.1 ADTC ToR October 2023

Written by: S Muir, Y Clark

Approved by: Area Drug and Therapeutics Committee Executive

Date of last revision: 14/08/2024

Date Approved: 30/10/2023

Date for Review: 30/10/2026



A small number of NHS GG&C posts will be aligned with permanent membership of the ADTC, including the following or their nominees:

- Director of Pharmacy
- Lead for Medicines Information
- Lead Pharmacist, Medicines Policy, Planning and Guidance
- Pharmacy Lead for Governance
- Pharmacy Lead for Prescribing Services
- Pharmacy Lead for Acute Services
- Pharmacy Lead for Non-medical Prescribing
- Medical Prescribing Advisor
- Medicines Planning Pharmacist

Chair

The Chief Executive (CE) appoints the ADTC Chair for a three-year term of office. One of the 2 Vice Chairs will normally be considered for this role, as follows:

- If a single expression of interest is received, endorsement by the CE is the final step.
- If two expressions of interest are received, the Head of Board Administration (or nominee), in consultation with the Director of Pharmacy, will establish a fair and equitable process for a final decision.
- If the Chair requires to be drawn from the membership of the ADTC, the Head of Board Administration (or nominee), in consultation with the Vice Chairs and the Director of Pharmacy, will establish a process for the election.

The position of ADTC Chair may be renewable for a number of subsequent three-year terms at the discretion of the ADTC Executive.

Vice Chairs

The Chair, in consultation with the ADTC Executive and the Director of Pharmacy, should appoint two Vice Chairs from the ADTC membership who should ideally come from different areas of clinical practice (i.e. different therapeutic specialties, different care settings or different professions). The Head of Board Administration (or nominee), in consultation with the Director of Pharmacy, will establish a process for this election (see Appendix 1 attached).

The position of ADTC Vice Chair constitutes a three-year term of office which may be renewable for a number of subsequent three-year terms at the discretion of the ADTC Executive.

Sub-Committee Chairs

There will also be a process for election of the Chairs of the ADTC Subcommittees. These appointments will normally be drawn from the Subcommittee membership. These positions also constitute a three-year term of office which may be renewable for a number of subsequent three-year terms at the discretion of the ADTC Executive. The Head of Board Administration (or nominee), in consultation with the Director of Pharmacy, will establish a process for this election (see Appendix 2 attached).

File name: 2.1 ADTC ToR October 2023

Written by: S Muir, Y Clark

Approved by: Area Drug and Therapeutics Committee Executive

Date of last revision: 14/08/2024

Date Approved: 30/10/2023

Date for Review: 30/10/2026



Executive

The ADTC Executive comprises Chair, Vice-Chairs, Professional Secretary, Lead Pharmacist for Medicines Policy, Planning and Guidance, Medical Prescribing Advisor and Lead Pharmacist – Governance and co-opted Sub-Committee Chairs as required.

Quorum:

A quorum of the Committee will be one third of its membership and should always include either the Chair or a Vice Chair.

Meetings:

Meetings will be convened bi-monthly (typically the second Monday of the even months). The Chairman has the authority to change the dates with appropriate advance notice.

Notice of meetings:

Secretariat support to the Area Drugs and Therapeutics Committee will be provided by NHS Greater Glasgow and Clyde staff. The agenda and papers for the meetings will be issued one week in advance of the meeting date.

Accountability:

Overall accountability is to the Chief Executive of NHS Greater Glasgow & Clyde, via the Board's Medical Director.

communication links:

ADTC will provide regular reports to the Prescribing Management Group on medicines management and the financial implications of medicine developments. In addition, ADTC will link closely with the Clinical Governance Forum

Minutes:

The approved minutes will be made available on the GGC Medicines website (www.ggcmedicines.org.uk).

File name: 2.1 ADTC ToR October 2023
Written by: S Muir, Y Clark

Approved by: Area Drug and Therapeutics Committee Executive

Date of last revision: 14/08/2024

Date Approved: 30/10/2023

Date for Review: 30/10/2026



APPENDIX 1

NHS GREATER GLASGOW AND CLYDE Area Drug and Therapeutics Committee

Process for selection of Vice Chair appointments

The ADTC is an advisory committee to the NHS Board. The Terms of Reference indicate there should be two Vice Chairs, ideally each representing a different area of clinical practice (i.e. different therapeutic specialties, different care settings or different professions). When the position of Vice Chair requires to be filled the following process should apply:-

- (a) All Members should be notified of the vacancy, together with information about the responsibilities, time commitment and role in support of the ADTC Chair and ADTC Executive.
- (b) The Head of Board Administration (or nominee) will invite all Members to express an interest in applying for the position. This can be a self-nomination or a nomination on behalf of another member, with that member's support.
- (c) A timescale of 15 working days will be set between the announcement inviting nominations to the deadline for receipt. Nominations should be submitted in confidence to the Head of Board Administration (or nominee). Subsequently, all nominations will be passed to the ADTC Chair, who will liaise with the remaining ADTC Vice Chair and the Director of Pharmacy.
- (d) Where only one Member has expressed an interest, the Chair and remaining Vice Chair will consider their relevant experience and thereafter make a recommendation to the Head of Board Administration (or nominee) to endorse any decision to appoint to the position.
- (e) If two or more Members express an interest in the position, the Chair will inform them both accordingly and will advise about a criteria-based approach to reach a recommendation (e.g. this may include time served as ADTC member, experience on ADTC Executive, leadership in ADTC policy matters, participation on ADTC Subcommittees, SMC / NDC membership). This exercise will be taken by a 'virtual panel' consisting of the Chair, Vice Chair and a third member of the ADTC Executive as deemed appropriate by the Chair.
- (f) The final recommendation will be submitted by the Chair to the Head of Board Administration (or nominee) who will then formally notify the successful candidate.

File name: 2.1 ADTC ToR October 2023 Date of last revision: 14/08/2024

Approved by: Area Drug and Therapeutics Committee Executive

Written by: S Muir, Y Clark

Page: 5 of 6

Date Approved: 30/10/2023

Date for Review: 30/10/2026



APPENDIX 2

NHS GREATER GLASGOW AND CLYDE Area Drug and Therapeutics Committee

Process for selection of Sub-Committee Chair appointments

The ADTC is an advisory committee to the NHS Board. The Terms of Reference indicate there should be a Chair for each Sub-Committee, each representing a different aspect of the work of the parent committee. When the position of Sub-Committee Chair requires to be filled the following process should apply:-

- (a) All Members of the relevant Sub-Committee should be notified of the vacancy, together with information about the responsibilities, time commitment and role in support of the ADTC and ADTC Executive.
- (b) The Head of Board Administration (or nominee) will invite all Members to express an interest in applying for the stated position. This can be a self-nomination or a nomination on behalf of another member, with that member's support.
- (c) A timescale of 15 working days will be set between the announcement inviting nominations to the deadline for receipt. Nominations should be submitted in confidence to the Head of Board Administration (or nominee). Subsequently, all nominations will be passed to the ADTC Chair, who will liaise with the ADTC Vice Chairs and the Director of Pharmacy.
- (d) Where only one Member has expressed an interest, the Chair and one of the Vice Chairs will consider their relevant experience and thereafter make a recommendation to the Head of Board Administration (or nominee) to endorse any decision to appoint to the position.
- (e) If two or more Members express an interest in the position, the Chair will inform them both accordingly and will advise about a criteria-based approach to reach a recommendation (e.g. this may include time served as ADTC member, experience on ADTC Executive, leadership in ADTC policy matters, participation on ADTC Subcommittees, SMC / NDC membership). This exercise will be taken by a 'virtual panel' consisting of the Chair, Vice Chair and a third member of the ADTC Executive as deemed appropriate by the Chair.
- (f) The final recommendation will be submitted by the Chair to the Head of Board Administration (or nominee) who will then formally notify the successful candidate.

File name: 2.1 ADTC ToR October 2023

Written by: S Muir, Y Clark

Approved by: Area Drug and Therapeutics Committee Executive

Date of last revision: 14/08/2024

Date Approved: 30/10/2023

Date for Review: 30/10/2026